Skip to main content
Atrás
Watch Compare

Nuo Therapeutics, Inc.

Calidad de datos: 83%
AURX
OTC Manufacturing Measuring & Analyzing Instruments
$1.70
$0.00 (0.00%)
Cap. Mercado: 82.09 M
Precio
$1.70
Cap. Mercado
82.09 M
Rango del Día
—
Rango de 52 Semanas
—
Volumen
—
Apertura —
Promedio 50D / 200D
—
Promedio 50D / 200D
—

Quick Summary

Puntos Clave

Negative free cash flow of -1.14 M

Crecimiento

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Calidad

Return on Equity
N/A
ROIC-385.42%
Net MarginN/A
Op. MarginN/A

Seguridad

Debt / Equity
N/A
Current Ratio1.16
Interest CoverageN/A

Valoración

PE (TTM)
-32.68
Below sector avg (-1.48)
P/B RatioN/A
EV/EBITDAN/A
Dividend YieldN/A

Historial de Precios

Tendencias Financieras

Comparación con Pares

vs mediana del sector Manufacturing (1366 pares)
Métrica Acción Mediana del Sector
P/E -32.7 -1.5
P/B — 1.6
ROE % — -53.5
Net Margin % — -41.5
Rev Growth 5Y % — 1.8
D/E — 0.3

Precio Objetivo de Analistas

1 analista
Buy
Actual
$1.70
+76.5%
Objetivo
$3.00
$3.00
$3.00
$3.00
Pronóstico
P/E Futuro -170.00
EPS Futuro -$0.01
Ingresos Est. 9.46 M

Estimaciones de Ganancias

Período EPS Est. Ingresos Est. Analistas
FY2027 -$0.01
-$0.01 – -$0.01
 9.46 M 1
FY2026 -$0.04
-$0.04 – -$0.04
 5.75 M 1

Sorpresas de Ganancias

Últimos 2 trimestres
Trimestre EPS Est. EPS Real Sorpresa
Q42025 -$0.01 -$0.01 0.0%
Q32025 N/A -$0.01 —

All Fundamental Metrics
Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) N/A Net Income (TTM) -2.51 M
ROE N/A ROA -152.85%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -1.14 M
ROIC -385.42% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 1.16
Interest Coverage N/A Asset Turnover N/A
Working Capital 206,167 Tangible Book Value -419,606
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -32.68 Forward P/E N/A
P/B Ratio N/A P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -1.39%
Market Cap 82.09 M Enterprise Value 81.58 M
Per Share
EPS (Diluted TTM) N/A Revenue / Share N/A
FCF / Share -0.02 OCF / Share -0.02
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 45.37%
SBC-Adj. FCF -1.22 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue — — — — —
Net Income -2.51 M -2.32 M -3.17 M -3.17 M -90,670.0
EPS (Diluted) — — — — -0.03
Gross Profit 2.22 M 1.06 M 482,433.0 93,036.0 0.0
Operating Income -2.52 M -2.46 M -3.17 M -3.32 M -90,670.0
EBITDA — — — — —
R&D Expenses — — — — 0.0
SG&A Expenses 4.73 M 3.52 M 3.65 M 3.41 M —
D&A — — — — 0.0
Interest Expense — — — — 0.0
Income Tax 0.0 0.0 0.0 0.0 0.0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 1.85 M 1.19 M 1.88 M 3.05 M 1.47 M
Total Liabilities 2.80 M 675,796.0 838,732.0 856,022.0 673,079.0
Shareholders' Equity -956,559.0 513,712.0 1.04 M 2.19 M 792,839.0
Total Debt — — — — 0.0
Cash & Equivalents 548,946.0 283,714.0 928,681.0 2.05 M 1.41 M
Current Assets 1.38 M 841,546.0 1.56 M 2.63 M 1.47 M
Current Liabilities 1.31 M 578,451.0 674,527.0 600,431.0 673,079.0